Abstract：
Anti-Interleukin-1 (Anti-IL-1) drugs are used to treat some chronic rheumatic diseases that can affect young people, including women of childbearing age. Two anti-IL-1 drugs are available in France: anakinra and canakinumab. Data on their use during pregnancy are still limited. Based on the published literature, we carried out a review of the use of these anti-IL-1 therapies during pregnancy: therapeutic indications, pharmacological profiles and assessment of embryonic, fetal and neonatal risks. Based on this analysis, and given the absence of any reported concern, it is possible to consider the use of these two treatments during pregnancy if the clinical situation so requires and under certain conditions. Based on the data available to date, anakinra should be preferred to canakinumab whenever possible.
摘要：
抗白细胞介素-1（抗IL-1）药物用于治疗一些可影响年轻人的慢性风湿性疾病，包括育龄妇女。法国有两种抗IL-1药物：anakinra和canakinumab。在怀孕期间使用它们的数据仍然有限。根据已发表的文献，我们对怀孕期间使用这些抗IL-1疗法进行了回顾：治疗适应症，药理学概况和胚胎评估，胎儿和新生儿的风险。基于这一分析,鉴于没有任何报道的关注，如果临床情况需要并且在某些情况下，可以考虑在怀孕期间使用这两种治疗方法。根据迄今为止可用的数据，在可能的情况下，应首选anakinra而不是canakinumab。
